[go: up one dir, main page]

WO2001011369A8 - Cancer treatments and diagnostics utilizing rad51 related molecules and methods - Google Patents

Cancer treatments and diagnostics utilizing rad51 related molecules and methods

Info

Publication number
WO2001011369A8
WO2001011369A8 PCT/US2000/022077 US0022077W WO0111369A8 WO 2001011369 A8 WO2001011369 A8 WO 2001011369A8 US 0022077 W US0022077 W US 0022077W WO 0111369 A8 WO0111369 A8 WO 0111369A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
related molecules
cancer treatments
rad51
cancer
Prior art date
Application number
PCT/US2000/022077
Other languages
French (fr)
Other versions
WO2001011369A1 (en
Inventor
Horst-Werner Stuerzbecher
Gurucharan Reddy
Original Assignee
Pangene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/454,495 external-priority patent/US6576759B2/en
Application filed by Pangene Corporation filed Critical Pangene Corporation
Priority to EP00955469A priority Critical patent/EP1204868A1/en
Priority to AU67673/00A priority patent/AU6767300A/en
Priority to JP2001515973A priority patent/JP2003506100A/en
Priority to CA002379608A priority patent/CA2379608A1/en
Publication of WO2001011369A1 publication Critical patent/WO2001011369A1/en
Publication of WO2001011369A8 publication Critical patent/WO2001011369A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Described herein are methods of treating, diagnosing and prognosing cancer, sensitizing a patient for treatment for cancer, providing predictive outcomes for treatments for cancer and methods of inducing apoptosis. Compositions, agents and kits are also provided.
PCT/US2000/022077 1999-08-10 2000-08-10 Cancer treatments and diagnostics utilizing rad51 related molecules and methods WO2001011369A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00955469A EP1204868A1 (en) 1999-08-10 2000-08-10 Cancer treatments and diagnostics utilizing rad51 related molecules and methods
AU67673/00A AU6767300A (en) 1999-08-10 2000-08-10 Cancer treatments and diagnostics utilizing rad51 related molecules and methods
JP2001515973A JP2003506100A (en) 1999-08-10 2000-08-10 Cancer treatment and diagnosis using Rad51-related molecules and methods
CA002379608A CA2379608A1 (en) 1999-08-10 2000-08-10 Cancer treatments and diagnostics utilizing rad51 related molecules and methods

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US14809199P 1999-08-10 1999-08-10
US14809299P 1999-08-10 1999-08-10
US60/148,091 1999-08-10
US60/148,092 1999-08-10
US15461699P 1999-09-17 1999-09-17
US60/154,616 1999-09-17
US45530099A 1999-12-06 1999-12-06
US09/454,495 US6576759B2 (en) 1999-02-10 1999-12-06 Antisense inhibition of RAD51
US09/454,495 1999-12-06
US09/455,300 1999-12-06

Publications (2)

Publication Number Publication Date
WO2001011369A1 WO2001011369A1 (en) 2001-02-15
WO2001011369A8 true WO2001011369A8 (en) 2001-04-05

Family

ID=27538317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022077 WO2001011369A1 (en) 1999-08-10 2000-08-10 Cancer treatments and diagnostics utilizing rad51 related molecules and methods

Country Status (5)

Country Link
EP (1) EP1204868A1 (en)
JP (1) JP2003506100A (en)
AU (1) AU6767300A (en)
CA (1) CA2379608A1 (en)
WO (1) WO2001011369A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013488A2 (en) * 2001-08-09 2003-02-20 Pangene Corporation Methods and compositions for inhibiting rad51
DK2099442T3 (en) 2006-12-26 2015-02-16 Pharmacyclics Inc Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
WO2008156827A2 (en) * 2007-06-20 2008-12-24 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Molecular grading methods for ductal carcinoma in situ
US8188252B2 (en) * 2008-11-17 2012-05-29 University Of Rochester Rad51 derived cancer cell specific promoters for targeted anti-cancer therapy
MX365393B (en) 2011-09-13 2019-05-31 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof.
WO2013153532A1 (en) 2012-04-12 2013-10-17 University Of Saskatchewan Phthalocyanine compounds useful as reca inhibitors and methods of using same
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037125A (en) * 1996-11-05 2000-03-14 Lexicon Genetics Incorporated Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51

Also Published As

Publication number Publication date
EP1204868A1 (en) 2002-05-15
WO2001011369A1 (en) 2001-02-15
CA2379608A1 (en) 2001-02-15
JP2003506100A (en) 2003-02-18
AU6767300A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
EP2468901A3 (en) Markers For Breast Cancer
ITMI951560A0 (en) FLUOROGENIC SUBSTRATES SUITABLE FOR PHOTOACTIVATION AFTER ENZYMATIC TRANSFORMATION, SUITABLE FOR THE DIAGNOSIS AND PHOTODYNAMIC THERAPY OF TUMORS
EP2009117A3 (en) Method for diagnosing pancreatic cancer
AU2002314901A1 (en) Methods of diagnosis and treatment of androgen-dependent prostate cancer, prostate cancer undergoing androgen-withdrawal, and androgen-independent prostate cancer
NO20023402D0 (en) Mixtures and Methods for the Treatment and Diagnosis of Prostate Cancer
WO2002056022A3 (en) Diagnostics, drug screening and treatment for cancer
AU2209800A (en) Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia
WO2004050026A3 (en) Compositions and methods for treating prostate cancer
AU2002953327A0 (en) Methods of diagnosing prognosing and treating activin associated diseases and conditions
WO2007041697A3 (en) Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
Kessel Subcellular targeting as a determinant of the efficacy of photodynamic therapy
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
WO2005046797A3 (en) Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
AU2001292579A1 (en) Methods and compounds for treating proliferative diseases
WO2001011369A8 (en) Cancer treatments and diagnostics utilizing rad51 related molecules and methods
WO2004055196A3 (en) Method for identifying risk of breast cancer and treatments thereof
WO2004031414A3 (en) Method for diagnosing prostate cancer
WO2003028629A3 (en) Chlorin photosensitizing agents for use in photodynamic therapy
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2004110245A3 (en) Combination therapy for cancer treatment
NO20002412L (en) Method of treating tumors and tumor cells using ex vivo activated T cells
WO2001065998A3 (en) Methods for the diagnosis and treatment of breast cancer
AU2002219137A1 (en) Diagnosis kit, dna chip, and methods for diagnosing or supervising the treatment of testicular cancer
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2004026120A3 (en) Methods for diagnosing and treating tumors and suppressing cd promoters

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2379608

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000955469

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000955469

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000955469

Country of ref document: EP